背包健客2025-01-25 22:34:43诺和诺德下一代减重疗法公布最新临床数据，36周体重下降22%！ 今日，诺和诺德公布了其每周一次皮下注射的单分子胰高血糖素样肽-1（GLP-1）受体和胰淀素受体双重激动剂amycretin，在治疗肥胖或超重患者的1b/2a期临床试验中获得的主要结果。 试验结果显示，接受最高剂量amycretin治疗的参与者在36周后体重降低22.0%。#诺和诺德#减重疗法#临床数据#GLP-1受体#胰淀素受体#amycretin#肥胖#超重#1b/2a期临床试验
The Spectator Index2025-01-07 16:00:01SCIENCE: Research published in PLOS Medicine finds that loneliness is a stronger risk factor for death than physical inactivity and obesity and is equivalent in its effect to smoking 15 cigarettes a d#PLOS医学#孤独#死亡风险#身体活动不足#肥胖#吸烟#研究
